Literature DB >> 28193090

Estimating False-Recent Classification for the Limiting-Antigen Avidity EIA and BED-Capture Enzyme Immunoassay in Vietnam: Implications for HIV-1 Incidence Estimates.

Neha S Shah1, Yen T Duong1, Linh-Vi Le2, Nguyen Anh Tuan3, Bharat S Parekh1, Hoang Thi Thanh Ha3, Quang Duy Pham4, Cao Thi Thu Cuc4, Trudy Dobbs1, Tran Hong Tram3, Truong Thi Xuan Lien4, Nick Wagar1, Chunfu Yang1, Amy Martin1, Mitchell Wolfe2, Nguyen Tran Hien3, Andrea A Kim1.   

Abstract

Laboratory tests that can distinguish recent from long-term HIV infection are used to estimate HIV incidence in a population, but can potentially misclassify a proportion of long-term HIV infections as recent. Correct application of an assay requires determination of the proportion false recents (PFRs) as part of the assay characterization and for calculating HIV incidence in a local population using a HIV incidence assay. From April 2009 to December 2010, blood specimens were collected from HIV-infected individuals attending nine outpatient clinics (OPCs) in Vietnam (four from northern and five from southern Vietnam). Participants were living with HIV for ≥1 year and reported no antiretroviral (ARV) drug treatment. Basic demographic data and clinical information were collected. Specimens were tested with the BED capture enzyme immunoassay (BED-CEIA) and the Limiting-antigen (LAg)-Avidity EIA. PFR was estimated by dividing the number of specimens classified as recent by the total number of specimens; 95% confidence intervals (CI) were calculated. Specimens that tested recent had viral load testing performed. Among 1,813 specimens (north, n = 942 and south, n = 871), the LAg-Avidity EIA PFR was 1.7% (CI: 1.2-2.4) and differed by region [north 2.7% (CI: 1.8-3.9) versus south 0.7% (CI: 0.3-1.5); p = .002]. The BED-CEIA PFR was 2.3% (CI: 1.7-3.0) and varied by region [north 3.4% (CI: 2.4-4.7) versus south 1.0% (CI: 0.5-1.2), p < .001]. Excluding specimens with an undetectable VL, the LAg-Avidity EIA PFR was 1.2% (CI: 0.8-1.9) and the BED-CEIA PFR was 1.7% (CI: 1.2-2.4). The LAg-Avidity EIA PFR was lower than the BED-CEIA PFR. After excluding specimens with an undetectable VL, the PFR for both assays was similar. A low PFR should facilitate the implementation of the LAg-Avidity EIA for cross-sectional incidence estimates in Vietnam.

Entities:  

Keywords:  HIV; epidemiology; incidence; prevention

Mesh:

Substances:

Year:  2017        PMID: 28193090      PMCID: PMC5745576          DOI: 10.1089/AID.2016.0203

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  26 in total

1.  Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion.

Authors:  Trudy Dobbs; Susan Kennedy; Chou-Pong Pau; J Steven McDougal; Bharat S Parekh
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

2.  Factors associated with incorrect identification of recent HIV infection using the BED capture immunoassay.

Authors:  Oliver Laeyendecker; Ron Brookmeyer; Amy E Oliver; Caroline E Mullis; Kevin P Eaton; Amy C Mueller; Lisa P Jacobson; Joseph B Margolick; Joelle Brown; Charles R Rinaldo; Thomas C Quinn; Susan H Eshleman
Journal:  AIDS Res Hum Retroviruses       Date:  2011-12-01       Impact factor: 2.205

3.  An automated genotyping system for analysis of HIV-1 and other microbial sequences.

Authors:  Tulio de Oliveira; Koen Deforche; Sharon Cassol; Mika Salminen; Dimitris Paraskevis; Chris Seebregts; Joe Snoeck; Estrelita Janse van Rensburg; Annemarie M J Wensing; David A van de Vijver; Charles A Boucher; Ricardo Camacho; Anne-Mieke Vandamme
Journal:  Bioinformatics       Date:  2005-08-02       Impact factor: 6.937

4.  Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay.

Authors:  John W Hargrove; Jean H Humphrey; Kuda Mutasa; Bharat S Parekh; J Steve McDougal; Robert Ntozini; Henry Chidawanyika; Lawrence H Moulton; Brian Ward; Kusum Nathoo; Peter J Iliff; Ekkehard Kopp
Journal:  AIDS       Date:  2008-02-19       Impact factor: 4.177

5.  Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein.

Authors:  Xierong Wei; Xin Liu; Trudy Dobbs; Debra Kuehl; John N Nkengasong; Dale J Hu; Bharat S Parekh
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

6.  Detection of diverse variants of human immunodeficiency virus-1 groups M, N, and O and simian immunodeficiency viruses from chimpanzees by using generic pol and env primer pairs.

Authors:  C Yang; B C Dash; F Simon; G van der Groen; D Pieniazek; F Gao; B H Hahn; R B Lal
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

Review 7.  HIV incidence estimation using the BED capture enzyme immunoassay: systematic review and sensitivity analysis.

Authors:  Till Bärnighausen; Thomas A McWalter; Zachary Rosner; Marie-Louise Newell; Alex Welte
Journal:  Epidemiology       Date:  2010-09       Impact factor: 4.822

8.  Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies.

Authors:  Yen T Duong; Maofeng Qiu; Anindya K De; Keisha Jackson; Trudy Dobbs; Andrea A Kim; John N Nkengasong; Bharat S Parekh
Journal:  PLoS One       Date:  2012-03-27       Impact factor: 3.240

9.  Recalibration of the limiting antigen avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypes.

Authors:  Yen T Duong; Reshma Kassanjee; Alex Welte; Meade Morgan; Anindya De; Trudy Dobbs; Erin Rottinghaus; John Nkengasong; Marcel E Curlin; Chonticha Kittinunvorakoon; Boonyos Raengsakulrach; Michael Martin; Kachit Choopanya; Suphak Vanichseni; Yan Jiang; Maofeng Qiu; Haiying Yu; Yan Hao; Neha Shah; Linh-Vi Le; Andrea A Kim; Tuan Anh Nguyen; William Ampofo; Bharat S Parekh
Journal:  PLoS One       Date:  2015-02-24       Impact factor: 3.240

10.  Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository.

Authors:  Reshma Kassanjee; Christopher D Pilcher; Sheila M Keating; Shelley N Facente; Elaine McKinney; Matthew A Price; Jeffrey N Martin; Susan Little; Frederick M Hecht; Esper G Kallas; Alex Welte; Michael P Busch; Gary Murphy
Journal:  AIDS       Date:  2014-10-23       Impact factor: 4.177

View more
  6 in total

Review 1.  Working With Persons Who Inject Drugs and Live in Rural Areas: Implications From China/Vietnam for the USA.

Authors:  Don C Des Jarlais; Theodore M Hammett; Binh Kieu; Yi Chen; Jonathan Feelemyer
Journal:  Curr HIV/AIDS Rep       Date:  2018-08       Impact factor: 5.071

2.  Go Where the Virus Is: An HIV Micro-epidemic Control Approach to Stop HIV Transmission.

Authors:  Michael M Cassell; Rose Wilcher; Reshmie A Ramautarsing; Nittaya Phanuphak; Timothy D Mastro
Journal:  Glob Health Sci Pract       Date:  2020-12-23

3.  Evaluation of the HIV-1 Polymerase Gene Sequence Diversity for Prediction of Recent HIV-1 Infections Using Shannon Entropy Analysis.

Authors:  Paballo Nkone; Shayne Loubser; Thomas C Quinn; Andrew D Redd; Oliver Laeyendecker; Caroline T Tiemessen; Simnikiwe H Mayaphi
Journal:  Viruses       Date:  2022-07-21       Impact factor: 5.818

Review 4.  A systematic review of limiting antigen avidity enzyme immunoassay for detection of recent HIV-1 infection to expand supported applications.

Authors:  Joseph Kin-On Lau; Nicholas Murdock; Jeffrey Murray; Jessica Justman; Neil Parkin; Veronica Miller
Journal:  J Virus Erad       Date:  2022-09-07

5.  Immunological markers for identifying recent HIV infection in North-West India.

Authors:  Chandar Kanta Chauhan; P V M Lakshmi; Vivek Sagar; Aman Sharma; Sunil K Arora; Rajesh Kumar
Journal:  Indian J Med Res       Date:  2020-09       Impact factor: 2.375

Review 6.  Use of HIV Recency Assays for HIV Incidence Estimation and Other Surveillance Use Cases: Systematic Review.

Authors:  Shelley N Facente; Eduard Grebe; Andrew D Maher; Douglas Fox; Susan Scheer; Mary Mahy; Shona Dalal; David Lowrance; Kimberly Marsh
Journal:  JMIR Public Health Surveill       Date:  2022-03-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.